肝素酶在非小细胞肺癌中的表达及其临床意义

背景与目的已有的研究表明,肝素酶的表达与肿瘤的发生有关。本研究通过肝素酶在非小细胞肺癌(NSCLC)中的表达情况,探讨肝素酶与NSCLC临床病理及其预后的关系。方法采用免疫组化检测66例NSCLC和15例相应癌旁正常肺组织中肝素酶的表达。结果66例NSCLC组织中肝素酶表达阳性率为74.2%,而正常支气管和肺泡上皮中无阳性表达;肝素酶表达与肺癌的临床分期(P=0.042)、淋巴结转移(P=0.005)有密切关系;肝素酶阳性表达组患者的5年生存率明显低于阴性组(P=0.025)。结论肝素酶在人肺癌组织中的表达较正常肺组织明显上调,并与肺癌的临床分期、淋巴结转移和患者的预后相关,但不能作为患者预后评估的独立指标。

The expression and clinical significance of heparanase in non-small cell lung cancer

Background and objective It has been proven that heparanase played an important role in tumorigenesis.The aim of this work is to investigate the level of expression of heparanase protein in non-small cell lung cancer(NSCLC) and to explore the relationship between heparanase expression and NSCLC histological types and prognosis.Methods Immunohistochemical method was used to detect the heparanase expression in the routinely paraffin-embedded sections of surgical specimen of 66 cases with NSCLC and 15 ones with normal lung tissues.Results Heparanase was highly expressed in lung cancer tissues(74.2%) while negative in epithelia of normal lung tissues.The expression of heparanase was significantly correlated with TNM stage(P=0.042) and lymphatic metastasis(P=0.005).The patients with positive heparanase expression had a significantly shorter survival rate than those with negative heparanase expression(P=0.025).Conclusion Heparanase has more expression in NSCLC than normal lung tissues.It was correlated with TNM stage and lymphatic metastasis and prognosis of NSCLC.However,heparanase expression is not an independent prognostic factor.